GLP-1

GLP-1 (glucagon-like peptide-1) is an incretin peptide of the native active sequence, supplied as a lyophilized powder for research and professional use. It is offered here as a reference catalog SKU for licensed practitioners and is not approved by the FDA for therapeutic use. As a naturally occurring gut-derived signaling peptide, GLP-1 and its receptor pathway have been a recurring focus of metabolic and endocrine investigation, and the native sequence is commonly used as a comparator and tool compound in preclinical and laboratory settings. This entry is provided as a professional reference for the Weight Loss & Metabolic research category and does not constitute patient-facing marketing.

• Investigated in metabolic research literature in connection with glucose-homeostasis and insulin-secretion signaling; individual results vary
• Studied in preclinical models for its reported role in appetite-related and satiety signaling pathways; individual results vary
• Examined as a reference and comparator peptide in incretin-axis and receptor-binding research
• Explored in laboratory settings for reported effects on gastric-motility and nutrient-handling pathways; reported observations and individual results vary
• Referenced in body-weight and energy-balance research as a tool compound for mechanistic study; individual results vary

Reference handling information only: typically supplied as a lyophilized powder. Reconstitute with bacteriostatic water (or another diluent at the ordering provider's discretion) by directing the stream against the vial wall rather than onto the powder, and swirl gently rather than shaking. Store unreconstituted vials frozen or refrigerated and protected from light and moisture per the certificate or label; keep reconstituted material refrigerated, protect it from light, and minimize freeze-thaw cycles. Allow vials to reach handling temperature before opening and inspect for clarity prior to use. This compound is provided for research and professional use only and is not approved by the FDA for therapeutic use. All clinical protocols, including any reconstitution ratios, concentrations, and use decisions, are determined solely by the licensed ordering provider; this is reference information only and not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, GLP-1 is described as an incretin hormone that engages the GLP-1 receptor, a G-protein-coupled receptor reported to be expressed across pancreatic, central-nervous-system, and gastrointestinal tissues. Proposed and studied mechanisms include glucose-dependent modulation of insulin signaling, attenuation of glucagon output, slowing of gastric emptying, and central signaling associated with satiety. These mechanistic descriptions are drawn from preclinical and laboratory investigation, are not established therapeutic claims, and observed effects vary by model; individual results vary.